Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Targeted Oncology Therapeutics

Published by Greystone Research Associates Product code 925944
Published Content info
Delivery time: 1-2 business days
Price
Back to Top
Targeted Oncology Therapeutics
Published: February 16, 2020 Content info:
Description

A number of factors are changing the way market participants view the cancer therapeutics market. These factors are evident in the disease targets and drug classes that comprise a significant number of recent trials. After decades of disappointment and missed financial objectives, the genetic underpinnings of disease are converging with improved computer-assisted pharmacological decision making. Market sector participants now find themselves pursuing realistic therapeutic strategies that have the potential to fulfill product strategies in both scientific and human terms.

What You Will Learn:

  • What is the market share of approved therapeutics?
  • What is the global supply picture for targeted therapeutics?
  • Who are the market leaders, by Indication? by Product?
  • What is the therapeutic coverage across all oncology indications? What are the product opportunities?
  • What are the established products in this space? by target, indication, API class, revenue?
  • What is the competitive picture for the major Oncology market segments?
  • Drug treatment resources
  • Competitive therapy map
  • Clinical trial activity
  • Who are the leading competitors in the field of next-generation therapeutics?
Table of Contents
Product Code: TJK353F

Table of Contents(SUMMARY)

  • The Recombinant Drug Ecosystem
  • Targeted Oncology Therapeutics Market Leaders
  • Oncology Biologics - Competitive Considerations
  • Approved Drugs for targeted Oncology Therapeutics
  • FDA-approved Drugs
  • EMA-approved Drugs
  • Biosimilars of Trastuzumab
  • EMA Approved Biosimilars
  • The Impact of Litigation on Biosimilar Product Launches
  • Targeted Oncology Therapeutics - Market Segments
  • Breast Cancers
  • Colorectal Cancers
  • Hematology Cancers
  • Lung Cancers
  • Melanomas
  • Metastatic Gastric Cancers
  • Neurological Cancers
  • Renal Cell Carcinomas
  • Urothelial Cancers
  • Supplier Competitive Assessments

Charts, Tables, Graphs, and Visualizations

  • Approved mAbs - Market Share by Product Activity
  • Global Supplier Activity Map
  • Targeted Oncology Market Leaders (Indications, Products)
  • FDA/EMA Approved Product Market Coverage by Supplier

Established Products (Baseline & Commercialization Summaries)

  • Adcetris (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Avastin (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Blincyto (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Cyramza (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Adcetris (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Darzalex (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Empliciti (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Erbitux (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Gazyva (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Herceptin (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Imfinzi (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Keytruda (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Opdivo (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Perjeta (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Rituxan (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Tecentriq (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Vectibix (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Yervoy (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Zevalin (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)

Emerging Products

  • Arzerra (Detailed Profiles, Indications, Supply Chain)
  • Bavencio (Detailed Profiles, Indications, Supply Chain)
  • Besponsa (Detailed Profiles, Indications, Supply Chain)
  • Enhertu (Detailed Profiles, Indications, Supply Chain)
  • Herzuma (Detailed Profiles, Indications, Supply Chain)
  • Kadcyla (Detailed Profiles, Indications, Supply Chain)
  • Kanjinti (Detailed Profiles, Indications, Supply Chain)
  • Lartruvo (Detailed Profiles, Indications, Supply Chain)
  • Libtayo (Detailed Profiles, Indications, Supply Chain)
  • Lumoxiti (Detailed Profiles, Indications, Supply Chain)
  • Mvasi (Detailed Profiles, Indications, Supply Chain)
  • Ogivri (Detailed Profiles, Indications, Supply Chain)
  • Omtruzant (Detailed Profiles, Indications, Supply Chain)
  • Padcev (Detailed Profiles, Indications, Supply Chain)
  • Polivy (Detailed Profiles, Indications, Supply Chain)
  • Portrazza (Detailed Profiles, Indications, Supply Chain)
  • Poteligeo (Detailed Profiles, Indications, Supply Chain)
  • Ruxience (Detailed Profiles, Indications, Supply Chain)
  • Truxima (Detailed Profiles, Indications, Supply Chain)
  • Unituxin (Detailed Profiles, Indications, Supply Chain)
  • Zirabev (Detailed Profiles, Indications, Supply Chain)
  • EMA Approved Biosimilars, All
  • EMA, Approved Biosimilars for Oncology Incications
  • Biosimilars, Patent Litigation Impact Map

Targeted Oncology Market Assessments

  • Breast Cancer - Drug Treatment Resource Map, by Type
  • Breast Cancer - Competitive Therapy Map, Total Revenue by Year
  • Breast Cancer - Clinical Trial Activity, Sponsor/Collaborator
  • Breast Cancer - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Breast Cancer - Clinical Trial Activity by Trial Phase
  • Colorectal Cancer - Drug Treatment Resource Map, by Type
  • Colorectal Cancer - Competitive Therapy Map, Total Revenue by Year
  • Colorectal Cancer - Clinical Trial Activity, Sponsor/Collaborator
  • Colorectal Cancer - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Colorectal Cancer - Clinical Trial Activity by Trial Phase
  • Hematology Cancers - Drug Treatment Resource Map, by Type
  • Hematology Cancers - Competitive Therapy Map, Total Revenue by Year
  • Hematology Cancers - Clinical Trial Activity, Sponsor/Collaborator
  • Hematology Cancers - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Hematology Cancers- Clinical Trial Activity by Trial Phase
  • Lung Cancers - Drug Treatment Resource Map, by Type
  • Lung Cancers - Competitive Therapy Map, Total Revenue by Year
  • Lung Cancers - Clinical Trial Activity, Sponsor/Collaborator
  • Lung Cancers - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Lung Cancers- Clinical Trial Activity by Trial Phase
  • Melanomas - Drug Treatment Resource Map, by Type
  • Melanomas - Competitive Therapy Map, Total Revenue by Year
  • Melanomas - Clinical Trial Activity, Sponsor/Collaborator
  • Melanomas - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Melanomas- Clinical Trial Activity by Trial Phase
  • Metastatic Gastric Cancers - Drug Treatment Resource Map, by Type
  • Metastatic Gastric Cancers - Competitive Therapy Map, Total Revenue by Year
  • Metastatic Gastric Cancers - Clinical Trial Activity, Sponsor/Collaborator
  • Metastatic Gastric Cancers - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Metastatic Gastric Cancers- Clinical Trial Activity by Trial Phase
  • Neurological Cancers - Drug Treatment Resource Map, by Type
  • Neurological Cancers - Competitive Therapy Map, Total Revenue by Year
  • Neurological Cancers - Clinical Trial Activity, Sponsor/Collaborator
  • Neurological Cancers - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Neurological Cancers- Clinical Trial Activity by Trial Phase
  • Renal Cell Carcinomas - Drug Treatment Resource Map, by Type
  • Renal Cell Carcinomas - Competitive Therapy Map, Total Revenue by Year
  • Renal Cell Carcinomas - Clinical Trial Activity, Sponsor/Collaborator
  • Renal Cell Carcinomas - Clinical Trial Activity, First-listed Interventional Therapeutic
  • Renal Cell Carcinomas- Clinical Trial Activity by Trial Phase
  • Urothelial Cancers - Drug Treatment Resource Map, by Type
  • Urothelial Cancers - Competitive Therapy Map, Total Revenue by Year

Supplier Competitive Assessments

Back to Top